Drug Abuse in Cardiovascular Diseases

[1]  B. Vitiello.  Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. , 2008, Child and adolescent psychiatric clinics of North America.

[2]  T. Milling,et al.  Therapeutic hypothermia in cocaine-induced cardiac arrest. , 2008, Annals of emergency medicine.

[3]  R. Cappato,et al.  Illicit drugs and cardiac arrhythmias in athletes , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[4]  Mark A Williams,et al.  Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? , 2007, International journal of cardiology.

[5]  D. Fatovich,et al.  Amphetamine‐related presentations to an inner‐city tertiary emergency department: a prospective evaluation , 2007, The Medical journal of Australia.

[6]  G. Jensen,et al.  Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen , 2007, Heart.

[7]  H. Turhan,et al.  Cocaine-induced acute myocardial infarction in young individuals with otherwise normal coronary risk profile: is coronary microvascular dysfunction one of the underlying mechanisms? , 2007, International journal of cardiology.

[8]  T. Rosén.  Supraphysiological Doses of Growth Hormone: Effects on Muscles and Collagen in Healthy Active Young Adults , 2007, Hormone Research in Paediatrics.

[9]  J. Gauthier.  [The heart and doping]. , 2006, Archives des maladies du coeur et des vaisseaux.

[10]  F. Pigozzi,et al.  ESC Study Group of Sports Cardiology Position Paper on adverse cardiovascular effects of doping in athletes , 2006, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[11]  M. Šebeštjen,et al.  Ventricular tachycardia induced by abuse of ephedrine in a young healthy woman , 2006, Wiener klinische Wochenschrift.

[12]  L. Avois,et al.  Human growth hormone doping in sport , 2006, British Journal of Sports Medicine.

[13]  J A Henry,et al.  Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. , 2006, British journal of anaesthesia.

[14]  Jun Guo,et al.  Molecular Determinants of Cocaine Block of Human Ether-á-go-go-Related Gene Potassium Channels , 2006, Journal of Pharmacology and Experimental Therapeutics.

[15]  Eric Collins,et al.  Effect of acute cocaine administration on the QTc interval of habitual users. , 2006, The American journal of cardiology.

[16]  S. Nissen.  ADHD drugs and cardiovascular risk. , 2006, The New England journal of medicine.

[17]  R. Friedman.  The changing face of teenage drug abuse--the trend toward prescription drugs. , 2006, The New England journal of medicine.

[18]  Ryan Calfee,et al.  Popular Ergogenic Drugs and Supplements in Young Athletes , 2006, Pediatrics.

[19]  W. Woltersdorf,et al.  Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand. , 2005, The New Zealand medical journal.

[20]  J. Mann,et al.  The medical management of depression. , 2005, The New England journal of medicine.

[21]  M. Link,et al.  Cardiovascular toxicities of performance-enhancing substances in sports. , 2005, Mayo Clinic proceedings.

[22]  R. Foale,et al.  Cannabis as a precipitant of cardiovascular emergencies. , 2005, International journal of cardiology.

[23]  C. Chong,et al.  Correction , 2005, Emergency Medicine Journal.

[24]  S. Karch.  Cocaine Cardiovascular Toxicity , 2005, Southern medical journal.

[25]  L. Grélot,et al.  Cannabis use to enhance sportive and non-sportive performances among French sport students. , 2005, Addictive behaviors.

[26]  U. McCann,et al.  Recognition and management of complications of new recreational drug use , 2005, The Lancet.

[27]  P. Vardas,et al.  Acute electrophysiologic effects of inhaled salbutamol in humans. , 2005, Chest.

[28]  R. Schofield,et al.  Dilated Cardiomyopathy and Acute Liver Injury Associated with Combined Use of Ephedra, γ‐Hydroxybutyrate, and Anabolic Steroids , 2005, Pharmacotherapy.

[29]  M. Roderick,et al.  Drug use in English professional football , 2005, British Journal of Sports Medicine.

[30]  E. Turillazzi,et al.  Myocardial disarray: an architectural disorganization linked with adrenergic stress? , 2005, International journal of cardiology.

[31]  Jim Miller.  Managing antidepression overdoses. , 2004, Emergency medical services.

[32]  R. Hawkins,et al.  Ergogenic Aids: A Review of Basic Science, Performance, Side Effects, and Status in Sports , 2004, The American journal of sports medicine.

[33]  T. Noakes.  Tainted glory--doping and athletic performance. , 2004, The New England journal of medicine.

[34]  B. Altura,et al.  Cocaine Induces Apoptosis in Primary Cultured Rat Aortic Vascular Smooth Muscle Cells: Possible Relationship to Aortic Dissection, Atherosclerosis, and Hypertension , 2004, International journal of toxicology.

[35]  O. Hovatta,et al.  Concomitant Abuse of Anabolic Androgenic Steroids and Human Chorionic Gonadotrophin Impairs Spermatogenesis in Power Athletes , 2004, International journal of sports medicine.

[36]  P. Kotwinski,et al.  EX filter wire usage in stenting right coronary artery lesion with diffuse aneurysmal dilatation , 2004, Heart.

[37]  W. Kindermann,et al.  Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? , 2004, Heart.

[38]  W. Mckenna,et al.  Spontaneous atrial fibrillation in a freestyle skier , 2004, British Journal of Sports Medicine.

[39]  R. Freudenberger,et al.  Ephedra–Associated Cardiomyopathy , 2004, The Annals of pharmacotherapy.

[40]  K. Saifeldeen,et al.  Delayed postanoxic encephalopathy after carbon monoxide poisoning , 2004, Emergency Medicine Journal.

[41]  C. White,et al.  Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine: a randomized controlled trial. , 2004, JAMA.

[42]  A. Tucker,et al.  Cardiac Arrhythmia in a Professional Football Player , 2003, The Physician and sportsmedicine.

[43]  R. Cuneo,et al.  Controversies regarding the effects of growth hormone on the heart. , 2003, Mayo Clinic proceedings.

[44]  R. Cappato,et al.  Arrhythmogenic effects of illicit drugs in athletes. , 2003, Italian heart journal : official journal of the Italian Federation of Cardiology.

[45]  R. Boucek,et al.  Effects of one year of recombinant human growth hormone (GH) therapy on cardiac mass and function in children with classical GH deficiency. , 2003, The Journal of clinical endocrinology and metabolism.

[46]  J. Karjalainen,et al.  Anabolic androgenic steroids produce dose-dependant increase in left ventricular mass in power atheletes, and this effect is potentiated by concomitant use of growth hormone. , 2003, International journal of sports medicine.

[47]  R. Clayton.  Cardiovascular function in acromegaly. , 2003, Endocrine reviews.

[48]  Paul G Shekelle,et al.  Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. , 2003, JAMA.

[49]  D. Nutt,et al.  Psychotropic Drugs, Cardiac Arrhythmia, and Sudden Death , 2003, Journal of clinical psychopharmacology.

[50]  A. Wilde,et al.  Absence of Calsequestrin 2 Causes Severe Forms of Catecholaminergic Polymorphic Ventricular Tachycardia , 2002, Circulation research.

[51]  P. Mehler,et al.  Torsade de Pointes Associated with Very-High-Dose Methadone , 2002, Annals of Internal Medicine.

[52]  Carlo Napolitano,et al.  Clinical and Molecular Characterization of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia , 2002, Circulation.

[53]  R. Bouchard,et al.  Informed Decision-Making on Sympathomimetic Use in Sport and Health , 2002, Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine.

[54]  A. Pipe,et al.  Nutritional Supplements and Doping , 2002, Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine.

[55]  H. Dean.  Does Exogenous Growth Hormone Improve Athletic Performance? , 2002, Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine.

[56]  A. Camm,et al.  Potential cardiac toxicity of H1-antihistamines. , 2002, Clinical allergy and immunology.

[57]  Stephen F. Miller,et al.  Supplements and drugs used to enhance athletic performance. , 2002, Pediatric clinics of North America.

[58]  D. Greenblatt,et al.  Selective serotonin reuptake inhibitor antidepressants: cardiovascular complications--sorting through findings. , 2001, Journal of clinical psychopharmacology.

[59]  D. Catlin,et al.  Analysis of Over-the-Counter Dietary Supplements , 2001, Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine.

[60]  M. Link,et al.  Report of the NASPE Policy Conference on Arrhythmias and the Athlete , 2001, Journal of cardiovascular electrophysiology.

[61]  J. Muller,et al.  Triggering Myocardial Infarction by Marijuana , 2001, Circulation.

[62]  B. Fridlund,et al.  The prevalence of the use of androgenic anabolic steroids by adolescents in a county of Sweden. , 2001, European journal of public health.

[63]  E. D. De Palo,et al.  Correlations of growth hormone (GH) and insulin-like growth factor I (IGF-I): effects of exercise and abuse by athletes. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[64]  D. Stephan,et al.  Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). , 2001, Human molecular genetics.

[65]  Fineschi,et al.  Anabolic steroid abuse and cardiac sudden death: a pathologic study. , 2001, Archives of pathology & laboratory medicine.

[66]  N. Benowitz,et al.  Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids , 2000 .

[67]  R. Svenson,et al.  Brugada-type electrocardiographic pattern induced by cocaine. , 2000, Mayo Clinic proceedings.

[68]  M. Dalrymple-Hay,et al.  Ventricular thrombosis and systemic embolism in bodybuilders: etiology and management. , 2000, The Annals of thoracic surgery.

[69]  W. Jelkmann,et al.  Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. , 2000, Current pharmaceutical biotechnology.

[70]  U. Kujala,et al.  Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. , 2000, International journal of sports medicine.

[71]  J. He,et al.  Cocaine induces apoptosis in human coronary artery endothelial cells. , 2000, Journal of cardiovascular pharmacology.

[72]  C. Yesalis,et al.  Doping among adolescent athletes. , 2000, Bailliere's best practice & research. Clinical endocrinology & metabolism.

[73]  B. Bengtsson,et al.  Growth hormone abuse. , 2000, Bailliere's best practice & research. Clinical endocrinology & metabolism.

[74]  J. B. Murray.  Cardiac Disorders and Antidepressant Medications , 2000, The Journal of psychology.

[75]  L. Horan,et al.  Comparative effects of sodium bicarbonate and sodium chloride on reversing cocaine-induced changes in the electrocardiogram. , 1999, Journal of cardiovascular pharmacology.

[76]  N R Webster,et al.  Increased mortality associated with growth hormone treatment in critically ill adults. , 1999, The New England journal of medicine.

[77]  M. Sullivan,et al.  Atrial fibrillation and anabolic steroids. , 1999, The Journal of emergency medicine.

[78]  J. Karjalainen,et al.  QT interval and QT dispersion in endurance athletes and in power athletes using large doses of anabolic steroids. , 1999, The American journal of cardiology.

[79]  S. Alvarez-Elcoro,et al.  The macrolides: erythromycin, clarithromycin, and azithromycin. , 1999, Mayo Clinic proceedings.

[80]  J. Muller,et al.  Triggering of myocardial infarction by cocaine. , 1999, Circulation.

[81]  D. Greenblatt,et al.  More on potassium, the heart, and antipsychotic agents. , 1999, Journal of clinical psychopharmacology.

[82]  S. Priori,et al.  Cardiovascular Safety of Second-Generation Antihistamines , 1999, American journal of rhinology.

[83]  R. Purssell,et al.  Cardiovascular toxicity after ingestion of "herbal ecstacy". , 1999, The Journal of emergency medicine.

[84]  L. Dubuske.  Second-generation antihistamines: the risk of ventricular arrhythmias. , 1999, Clinical therapeutics.

[85]  P. Gennis,et al.  The cardiac toxicity of anabolic steroids. , 1998, Progress in cardiovascular diseases.

[86]  C. Flexner.  HIV-protease inhibitors. , 1998, The New England journal of medicine.

[87]  R. Blakely,et al.  Pharmacological profile of antidepressants and related compounds at human monoamine transporters. , 1997, European journal of pharmacology.

[88]  W. Frishman,et al.  Cardiovascular toxicity with cancer chemotherapy. , 1997, Current problems in cardiology.

[89]  R. Perera,et al.  Prolonged QT interval and cocaine use. , 1997, Journal of electrocardiology.

[90]  W. Mcconathy,et al.  Testosterone, Sex Hormone-Binding Globulin, Lipoproteins, and Vascular Disease Risk , 1997, Journal of cardiovascular risk.

[91]  V. Verdile,et al.  Anabolic steroid use as the possible precipitant of dilated cardiomyopathy. , 1997, Cardiology.

[92]  M. Nieminen,et al.  Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. , 1996, European heart journal.

[93]  P. Rolan.  Pharmacokinetics of New Antiherpetic Agents , 1995, Clinical pharmacokinetics.

[94]  R. Melchert,et al.  Cardiovascular effects of androgenic-anabolic steroids. , 1995, Medicine and science in sports and exercise.

[95]  L. Hillis,et al.  Influence of cocaine, ethanol, or their combination on epicardial coronary arterial dimensions in humans. , 1995, Archives of internal medicine.

[96]  E. Mini,et al.  Adverse Effects of Macrolide Antibacterials , 1993, Drug safety.

[97]  M. Kryger,et al.  Benzodiazepines in congestive heart failure: effects of temazepam on arousability and Cheyne-Stokes respiration. , 1993, Sleep.

[98]  D. Greenblatt,et al.  Use of benzodiazepines in anxiety disorders. , 1993, The New England journal of medicine.

[99]  Schollert Pv,et al.  Dilated cardiomyopathy in a user of anabolic steroids , 1993 .

[100]  R. Hoffman,et al.  Cocaine-induced myocardial infarction: an analysis and review of the literature. , 1992, The Journal of emergency medicine.

[101]  T. Randall.  Cocaine, alcohol mix in body to form even longer lasting, more lethal drug. , 1992, JAMA.

[102]  R. Kloner,et al.  The effects of acute and chronic cocaine use on the heart. , 1992, Circulation.

[103]  P. Grayburn,et al.  Left Ventricular Hypertrophy Associated With Chronic Cocaine Abuse , 1991, Circulation.

[104]  R. Watts.  Severe and fatal anthracycline cardiotoxicity at cumulative doses below 400 mg/m2: Evidence for enhanced toxicity with multiagent chemotherapy , 1991, American journal of hematology.

[105]  M. Lader,et al.  Cardiovascular effects of antidepressants , 1990, Psychological medicine. Monograph supplement.

[106]  S. Hale,et al.  Electrocardiographic abnormalities after acute administration of cocaine in the rat. , 1989, The American journal of cardiology.

[107]  P. Demacker,et al.  Deleterious Effects of Anabolic Steroids on Serum Lipoproteins, Blood Pressure, and Liver Function in Amateur Body Builders , 1988, International journal of sports medicine.

[108]  K. Phadke,et al.  Myocardial infarction due to amphetamine. , 1987, British medical journal.

[109]  D. Luchins,et al.  Monoamine oxidase inhibitors and tricyclic antidepressants: comparison of their cardiovascular effects. , 1986, The Journal of clinical psychiatry.

[110]  R. Gottlieb,et al.  Chemotherapy and cardiotoxicity. , 2008, Reviews in cardiovascular medicine.

[111]  G. Currier,et al.  Behavioural Manifestations of Anabolic Steroid Use , 2005, CNS drugs.

[112]  Harm Kuipers,et al.  Effects of Androgenic-Anabolic Steroids in Athletes , 2004, Sports medicine.

[113]  M. Yamada,et al.  Clinical pharmacology of MAO inhibitors: safety and future. , 2004, Neurotoxicology.

[114]  H. Dickhuth,et al.  Hypertrophic cardiomyopathy--sports-related aspects of diagnosis, therapy, and sports eligibility. , 2004, International Journal of Sports Medicine.

[115]  M. Yonamine,et al.  Marijuana as Doping in Sports , 2003, Sports medicine.

[116]  R. Wilber.  Detection of DNA-Recombinant Human Epoetin-Alfa as a Pharmacological Ergogenic Aid , 2002, Sports medicine.

[117]  B. Lund,et al.  Anabolic Steroids , 2002, Sports medicine.

[118]  I. Thiblin,et al.  Cause and manner of death among users of anabolic androgenic steroids. , 2000, Journal of forensic sciences.

[119]  G. Billman.  Cocaine: a review of its toxic actions on cardiac function. , 1995, Critical reviews in toxicology.

[120]  J. Russell,et al.  Anabolic steroid-induced tendon pathology: a review of the literature. , 1991, Medicine and science in sports and exercise.

[121]  M. Costanza,et al.  5‐Fluorouracil‐associated cardiotoxicity , 1988, Cancer.